Profiel
Seema Singh Bhan is a passionate leader who brings over two decades of experience in government affairs, public policy and advocacy.
Standing squarely at the intersection of transformative science and public policy, she is driven by her commitment to promote access for all to benefit from breakthroughs in science and technology.
Seema most recently served as Senior Vice President of Public Policy and External Affairs at Thrive Earlier Detection (now an Exact Sciences Company).
In the multi-cancer early detection space at Thrive she built the strategy that aligned and ignited policy partners–elected officials, patient advocates, and leaders across the public, private and academic sectors–around a bipartisan effort to ensure policies were in place for the adoption of such groundbreaking cancer diagnostics.
Prior to joining Thrive, Seema was Vice President, Head of Public Policy for Foundation Medicine, where she developed and executed company positions before Congress and other policymakers, including the landmark parallel review decision by the US Food and Drug Administration and the Centers for Medicare and Medicaid Services around next generation sequencing.
She was instrumental in ensuring broad health insurance reimbursement for Foundation Medicine’s flagship test, FoundationOne CDx.
Seema has also spent well over a decade in public service as senior counsel to Senator Arlen Specter and the Senate Judiciary Committee, where she was lead policy and strategic advisor for key issues including those related to tax, banking, healthcare and finance.
She provided policy analysis and strategic counsel to both Chairman Specter and Republican and Democrat senators on the Committee.
Seema lives outside of Philadelphia with her husband and two sons.
She loves spending time outdoors, exploring and supporting all Philly sports teams.
Actieve functies van Seema Bhan
| Bedrijven | Functie | Begin |
|---|---|---|
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Develops a ribonucleic acid-based liquid biopsy platform for early cancer detection | Consultant / Adviseur | 02-01-2023 |
Section 32 LLC
Section 32 LLC Investment ManagersFinance Section 32 invests in companies located in the United States. The firm focuses on companies operating in the field of technology sector. It provides financing for early stage capital requirements. | Consultant / Adviseur | - |
Eerdere bekende functies van Seema Bhan
| Bedrijven | Functie | Einde |
|---|---|---|
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Develops liquid biopsy test that is designed to detect cancers at early stages | Private Equity Investor | 31-01-2023 |
Foundation Medicine GmbH
Foundation Medicine GmbH Miscellaneous Commercial ServicesCommercial Services Provides technical testing and analysis services | Private Equity Investor | 30-09-2019 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Section 32 LLC
Section 32 LLC Investment ManagersFinance Section 32 invests in companies located in the United States. The firm focuses on companies operating in the field of technology sector. It provides financing for early stage capital requirements. | Finance |
Foundation Medicine GmbH
Foundation Medicine GmbH Miscellaneous Commercial ServicesCommercial Services Provides technical testing and analysis services | Commercial Services |
Thrive Earlier Detection Corp.
Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Develops liquid biopsy test that is designed to detect cancers at early stages | Health Technology |
Exai Bio, Inc.
Exai Bio, Inc. Packaged SoftwareTechnology Services Develops a ribonucleic acid-based liquid biopsy platform for early cancer detection | Technology Services |
















